Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Brassicasterol.
A phytosterol primarily derived from rapeseed and marine algae that modulates lipid metabolism and exhibits neuroprotective potential through the inhibition of beta-amyloid aggregation.
5283653
398.7 g/mol
8.7
(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5,6-dimethylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Brassicasterol across standard consumer modalities.
High lipophilicity requires co-formulation with oil-based carriers or surfactants to prevent poor dissolution and erratic bioavailability.
The hydrophobic nature of brassicasterol can lead to phase separation or a waxy mouthfeel in aqueous pectin or gelatin matrices.
Low water solubility and high dose requirements for therapeutic efficacy significantly limit the payload capacity of thin-film polymer matrices.
Ready to launch a product featuring Brassicasterol? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Brassicasterol extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Brassicasterol payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation